Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

Focus on Cystic Fibrosis Planned for Vertex’s 2016 R&D Program

Vertex Pharmaceuticals, a biotech company that discovers, develops, and commercializes medicines for a series of diseases, currently with a clinical development program focused on cystic fibrosis (CF), recently announced its key business priorities for 2016. Vertex currently has two medicines approved for cystic fibrosis treatment: KALYDECO (ivafactor) and ORKAMBI (lumacaftor/ivacaftor).

Cystic Fibrosis Bacteria, Recently ID’d, Spread Among Patients at CF Center

A new study report for a first time an “epidemic spread” of Pandoraea pulmonicola, a bacterial species that belongs to the recently identified genus Pandoraea spp. and which is associated with cystic fibrosis (CF), among patients at a CF center in France. The article, published in BMC Infectious Diseases, is titled “Epidemic spread of Pandoraea pulmonicola in a cystic fibrosis…

3 New CF Virulence Factors ID’d in Genome-wide Screen of Pathogen

In a new study, researchers describe the results of a genome-wide screen of Pseudomonas aeruginosa in a yeast, which led to the identification of three potential new Pseudomonas virulence factors. The research paper, entitled “Genome-wide Screen of Pseudomonas aeruginosa in Saccharomyces cerevisiae Identifies New Virulence Factors,” was published in Frontiers in Cellular and…

Translarna, a Novel CF Therapy, Advances in 2nd Clinical Trial

PTC Therapeutics Inc. has announced the completion of patient enrollment in its second Phase 3 clinical trial of the experimental cystic fibrosis therapy Translarna™. The clinical trial, named ACT CF, is a placebo controlled study designed to evaluate the efficacy of Translarna (ataluren) in patients, age 6 or older, with nonsense…

Experimental CF Therapy CTP-656 by Concert Pharma Begins New Round of Testing

Concert Pharmaceuticals, Inc., a clinical stage pharmaceutical company that focuses on the development of new small molecule drugs through its DCE (deuterated chemical entity) Platform®, has announced the beginning of Phase 1 multiple ascending dose clinical trial with its cystic fibrosis treatment CTP-656 (deuterium-modified ivacaftor). The announcement follows recent news…

Patent Granted to OrPro Therapeutics’ Lead Candidate Theradux™ for Treatment of Cystic Fibrosis

OrPro Therapeutics, Inc. has announced it has been granted a patent by the US Patent and Trademark Office (USPTO) for its lead candidate Theradux™, covering its unique treatment ability for cystic fibrosis (CF). The company has been developing a treatment pipeline based on thioredoxin, a naturally secreted protein with enzymatic activity known to have…